Company Overview
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients.
Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists' existing workflow.
The lead product Histotype Pxae Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.
Mission
DoMore Diagnostics was established to meet the need for novel methods in precision medicine to personalize treatment for cancer patients and is based on prominent research from institutions such as Oslo University Hospital, Oxford University, and University College of London.
The research project was a Lighthouse project by the Norwegian Research Council to develop new AI-based diagnostic methods in cancer.
The project aims to utilize new AI technology in digital pathology to reduce over- and undertreatment in cancer.
DoMore Diagnostics is on a mission to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes at lower healthcare costs.
Leadership and Team
- Torbjørn Furuseth, MD - Chief Executive Officer (CEO) & Co-founder. Experienced executive with a broad life sciences background; Medical Doctor from Norwegian University of Science and Technology.
- Sepp De Raedt, PhD - Chief Technology Officer (CTO) & Co-founder. Expert in machine learning applications in radiology and pathology; MSc from Delft University of Technology and PhD from Aarhus University.
- Elisabeth M.J. Klaussen, MSc - Head of Quality and Regulatory. Experienced in quality assurance in pharma, biotech, and medtech; MSc in Biology from University of Oslo.
- Andreas Berg Storsve, PhD - VP Operations. Background in R&D, strategy, and business development; MSc in Experimental Psychology from UNSW Sydney, PhD from University of Oslo.
- Lao Saal, MD, PhD - Medical Director. Cancer scientist and entrepreneur focused on advancing cancer research with precision medicine; MD and PhD from Columbia University.
Board of Directors and Scientific Advisors
- Tomas Nordheim Alme, MD - Chairman. Pediatrician with management experience and an MBA from the Norwegian School of Economics.
- Øyvind Grotmol, MSc - Director. Serial tech entrepreneur, Founder and CTO of Exabel; MSc in Electronics & Computer Science from NTNU.
- Yngve Tvedt, MBA - Director. Founder and CIO of Norselab, an impact investment platform.
- Knut Liestøl, Prof - Director. Professor and former department head at University of Oslo.
- Ketil F. Widerberg, MBA - Director. Experienced in life science and software industries, Managing Director for Oslo Cancer Cluster; MBA from University of Cambridge.
Scientific Advisory Board
- Dr. John L. Marshall, MD - Oncology CMO for Indivumed. International expert in GI cancer drug development and precision medicine.
- Dr. Jeanine Roodhart, MD, PhD - Medical oncologist and associate professor specialized in colorectal cancer research and personalized treatment.
- Dr. Takayuki Yoshino, MD - Deputy Director at National Cancer Center Hospital East, Japan, expert in gastrointestinal oncology.
- Dr. Frank A. Sinicrope, MD, FACP - Professor of oncology at Mayo Clinic, expert in colorectal cancer and predictive biomarkers.
- Prof. Marc Peeters, MD - CEO of Antwerp University Hospital and Professor of oncology, involved in colorectal cancer research.
- Prof. Marco Novelli, MD - Professor of gastrointestinal pathology at University College London, expert in colorectal cancer and AI in pathology.
- Prof. Hans-Joachim Schmoll, MD - Head of clinical oncology research at University Hospital of Halle, global leader in GI oncology.